This Morgan Stanley fund is trouncing the market this year. Here's what it's betting on now

Published Tue, May 19 20207:21 AM EDT

Jesse Pound @/in/jesse-pound @jesserpound

This story is for CNBC Pro subscribers only. A Morgan Stanley mutual fund that is focused on growth stocks and is beating the market by more than 30% this year has several large positions in health care and tech names, according to fund's most recent filing. ( Read more about the fund here . ) The Insight Fund is run by Dennis Lynch, who is the head of Counterpoint Global at Morgan Stanley Investment Management. The fund has 38 stocks, and is heavily weighted toward the tech sector. It also had a 5.3% weight in cash at quarter end. The firm's biggest position is in Amazon , the tech giant which has continued to grow during the pandemic. The 59,202 shares the fund had in Amazon as of quarter end would currently be worth around $141 million. Then there is Zoom . The video conferencing stock, which has exploded in recent months as workers and their employers have scrambled to figure out working from home en masse, was previously held in another Counterpoint Global product, Lynch said, but it was added to the Insight Fund during the fourth quarter of last year. It made up just under 5% of the fund's value as of March 31. Zoom is not the only work-from-home stock where the Insight Fund has a large position. Slack accounted for 5.3% of the portfolio as of March 31, and MongoDB took up another 4.6%. The fund's second largest sector is health care, accounting for 25% at the end of the first quarter. As of March 31 the fund's stakes in Intuitive Surgical , Illumina and NanoString Technologies totaled just under 10% of the total portfolio. The growth of the health care sector makes it a natural target for the Insight Fund, Lynch said, but the investment team is careful to companies that aren't as exposed to potential regulatory changes. "We try to stick to companies that are less exposed to reimbursement risk but that add value hopefully long-term to the system by providing, in the case of genetic sequencing, research and innovation potential for people who are trying to benefit there," Lynch said.

A man wearing a protective mask sits on top of the Charging Bull sculpture near Wall St. amid the coronavirus pandemic on April 19, 2020 in New York City, United States.

Alexi Rosenfeld | Getty Images

This story is for CNBC Pro subscribers only.

A Morgan Stanley mutual fund that is focused on growth stocks and is beating the market by more than 30% this year has several large positions in health care and tech names, according to fund's most recent filing.

(Read more about the fund here.)

The Insight Fund is run by Dennis Lynch, who is the head of Counterpoint Global at Morgan Stanley Investment Management. The fund has 38 stocks, and is heavily weighted toward the tech sector. It also had a 5.3% weight in cash at quarter end.